Spero Therapeutics (SPRO) Revenue (2016 - 2026)

Spero Therapeutics has reported Revenue for 11 years, with the latest figure at $258000.0 in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 95.61% year-over-year to $258000.0; the trailing twelve-month figure through Mar 2026 stood at $12.5 million (down 70.21% YoY), and the FY2025 full-year result was $12.6 million, down 73.74% from the prior year.
• Revenue for Q1 2026 stood at $258000.0, up from -$7.3 million in the prior quarter.
• The five-year high for Revenue was $65.5 million in Q4 2023, with the low at -$7.3 million in Q4 2025.
• Historically, Revenue has averaged $9.1 million across 5 years, with a median of $2.7 million in 2023.
• The largest YoY upside for Revenue was 8272.31% in 2025 against a maximum downside of 124.29% in 2025.
• Spero Therapeutics' Revenue stood at $16.8 million in 2022, then soared by 290.72% to $65.5 million in 2023, then sank by 53.84% to $30.3 million in 2024, then tumbled by 124.29% to -$7.3 million in 2025, then surged by 103.51% to $258000.0 in 2026.
• The last three Revenue figures came in at $258000.0 (Q1 2026), -$7.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.